1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Metastases

Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]

Discontinued [GID-TA11004]

  • Project information
  • Project documents

27041-Pembrolizumab-Enzalutamide-for-Prostate-Cancer-V1.0-FEB2022-NONCONF.pdf (nihr.ac.uk)